First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension

Eur Respir J. 2018 Mar 1;51(3):1701694. doi: 10.1183/13993003.01694-2017. Print 2018 Mar.

Cécile Daccord¹, Igor Letovanec², Patrick Yerly³, Jonathan Bloch⁴, Adam Ogna¹, Laurent P Nicod^{1

5}, John-David Aubert^{6

5}

¹ Dept of Respiratory Medicine, Lausanne University Hospital, Lausanne, Switzerland.
² Dept of Pathology, Lausanne University Hospital, Lausanne, Switzerland.
³ Dept of Cardiology, Lausanne University Hospital, Lausanne, Switzerland.
⁴ Service and Central Laboratory of Hematology, Oncology Dept, Lausanne University Hospital, Lausanne, Switzerland.
⁵ Lung Transplantation Unit, Lausanne University Hospital, Lausanne, Switzerland.
⁶ Dept of Respiratory Medicine, Lausanne University Hospital, Lausanne, Switzerland john-david.aubert@chuv.ch.

No abstract available

Publication types